Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance

Kawada, Manabu; Inoue, Hiroyuki; Usami, Ihomi; Takamoto, Kozo; Masuda, Tohru; Yamazaki, Yasuharu; Ikeda, Daishiro

doi:10.1016/j.canlet.2005.10.040

Cited by 19 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as in the case of the variable growth response to the cytokine, different experimental conditions and IL-6 concentrations may account for the unequal results. The same authors isolated a new cytokine-resistant cell line, LNCaP-CR, by co-culturing LNCaP cells with WI-38 fibroblasts, in the presence of IL-1b ( Kawada et al, 2006). Similarly to our findings obtained in LNCaP-IL-6 þ cells, this new cell line was shown to be resistant to the cytotoxic action of IL-6.…”

Section: Discussionsupporting

confidence: 69%

“…Treatment with IL-6 led to the induction of apoptosis in LNCaP parental and control cells but not in LNCaP-IL-6 þ cells. To the best of our knowledge, the only data related to the IL-6 effect on LNCaP cell death are those published very recently by Kawada et al (2006). The authors reported that IL-6 alone is not effective in inducing DNA fragmentation or caspase-3-like activities in those cells.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

et al. 2006

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 98%

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

et al. 2006

View full text Add to dashboard Cite

“…Angiogenin expression is upregulated in a variety of tumor cells and its concentration in plasma is elevated in many types of cancer patients [10ϳ13]. We previously established a highly tumorigenic human androgen receptor-positive prostate cancer cell, LNCaP-CR (cytokine resistance) cell line, having inflammatory cytokine resistance [14]. Furthermore, we have recently reported that LNCaP-CR cell line overexpresses angiogenin and that knockdown of angiogenin expression by transfecting angiogenin small interfering RNA into LNCaP-CR inhibits the tumor growth of LNCaP-CR cells in SCID mice [15].…”

Section: Introductionmentioning

confidence: 99%

A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis

et al. 2008

Self Cite

View full text Add to dashboard Cite

Angiogenesis is a critical step for the tumor therapy. Many angiogenic factors are involved in the tumor angiogenesis. In the course of our screening for inhibitors of angiogenin secretion, one of angiogenic factors, we have isolated a new terrein glucoside (1) and terrein (2) from the fermentation broth of fungal strain Aspergillus sp. PF1381. The structure and absolute stereochemistry of 1 was determined to be (4S,5R)-5-[(a -D-glucopyranosyl)oxy]-4-hydroxy-3-(E-1-propenyl)-2-cyclopenten-1-one on the basis of spectral and enzymatic analyses. Compounds 1 and 2 equally inhibited angiogenin secretion from androgendependent prostate cancer cells, LNCaP-CR, with IC 50 values of 13 mM. However, both compounds did not affect VEGF secretion, another angiogenic factor. Furthermore, both compounds inhibited tube formation of human umbilical vein endothelial cells (HUVEC). These results suggested that 1 and 2 act as angiogenesis inhibitors through the inhibition of angiogenin secretion.

show abstract

“…Human androgen-dependent prostate cancer LNCaP cells make palpable tumors only when injected into nude mice56. We previously established a highly tumorigenic subline, LNCaP-CR cells, from parental LNCaP cells by the selection in cytokine-induced apoptosis resistance56.…”

mentioning

confidence: 99%

“…We previously established a highly tumorigenic subline, LNCaP-CR cells, from parental LNCaP cells by the selection in cytokine-induced apoptosis resistance56. LNCaP cells were killed by the treatment with IL-1β and IL-6, but LNCaP-CR cells were not5.…”

mentioning

confidence: 99%

A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo

Kawada

Inoue

Kajikawa

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

To create a new anti-tumor antibody, we conducted signal sequence trap by retrovirus-meditated expression method and identified coxsackie virus and adenovirus receptor (CXADR) as an appropriate target. We developed monoclonal antibodies against human CXADR and found that one antibody (6G10A) significantly inhibited the growth of subcutaneous as well as orthotopic xenografts of human prostate cancer cells in vivo. Furthermore, 6G10A also inhibited other cancer xenografts expressing CXADR, such as pancreatic and colorectal cancer cells. Knockdown and overexpression of CXADR confirmed the dependence of its anti-tumor activity on CXADR expression. Our studies of its action demonstrated that 6G10A exerted its anti-tumor activity primarily through both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Moreover, 6G10A reacted with human tumor tissues, such as prostate, lung, and brain, each of which express CXADR. Although we need further evaluation of its reactivity and safety in human tissues, our results show that a novel anti-CXADR antibody may be a feasible candidate for cancer immunotherapy.

show abstract

Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance

Cited by 19 publications

References 10 publications

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis

A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo

Contact Info

Product

Resources

About